erlotinib hydrochloride has been researched along with thalidomide in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (thalidomide) | Trials (thalidomide) | Recent Studies (post-2010) (thalidomide) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 9,789 | 1,385 | 4,342 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | thalidomide (IC50) |
|---|---|---|---|
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 7.8 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.37 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.5 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.38 | |
| Protein cereblon | Homo sapiens (human) | 1.38 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldman, B | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 1 |
| Curtiss, FR | 1 |
| Chen, Y; Fang, P; Sun, GP; Wang, GH; Wang, SH; Wu, PF; Wu, YQ; Zhang, LH; Zuo, G | 1 |
| Belal, A; Ma, X; O Aboelez, M; Xiang, G | 1 |
1 review(s) available for erlotinib hydrochloride and thalidomide
| Article | Year |
|---|---|
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
4 other study(ies) available for erlotinib hydrochloride and thalidomide
| Article | Year |
|---|---|
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Thalidomide | 2018 |
Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Mutation; Protein Kinase Inhibitors; Structure-Activity Relationship; Thalidomide | 2022 |